AbbVie Inc. $ABBV has recently taken a significant step toward growth by agreeing to pay $2.2 billion for an experimental obesity treatment developed by the Danish biotechnology firm Gubra A/S. This agreement opens the door for AbbVie to enter the highly competitive weight loss drug market that is rapidly evolving and attracting major players.